Relmada Therapeutics Celebrates Nasdaq Compliance Success
Relmada Therapeutics, Inc. (Nasdaq: RLMD) proudly announces its recent achievement of compliance with Nasdaq's minimum bid price requirement. This milestone demonstrates the company's resilience in the biotechnology sector, where it strives to develop innovative therapies aimed at treating oncology-related and central nervous system illnesses.
Understanding Compliance Requirements
On September 15, 2025, Relmada received official notice from the Nasdaq Stock Market LLC, confirming its fulfillment of the $1.00 minimum bid price requirement as stipulated under Nasdaq Listing Rule 5550(a)(2). This accomplishment required Relmada’s stocks to maintain a closing bid price of $1.00 for a continuous stretch of 10 business days. The company achieved this pivotal requirement on September 12, 2025, concluding the matter with Nasdaq.
By reaching this benchmark, Relmada reassures its investors and stakeholders of its strong market position, reiterating its commitment to ongoing growth and innovation in the biotechnology space.
Commitment to Innovative Therapies
As a clinical-stage biotechnology company, Relmada is at the forefront of developing groundbreaking treatments for significant health challenges. With its leading candidates—NDV-01 and sepranolone—currently progressing through mid-stage clinical trials, the company is focused on addressing daunting needs in both oncology and central nervous system domains.
Clinical Trials and Future Prospects
Relmada is deeply invested in the advancement of its clinical trials, believing that these therapies could provide solutions for patients in need. The impressive potential of NDV-01 to yield favorable results is particularly promising, as the company anticipates the release of further trial data. These developments hold the key to making an impactful difference in patient lives.
Looking Ahead
Now that Relmada has regained compliance, its stock will continue to be listed and actively traded on the Nasdaq Capital Market under the ticker symbol “RLMD.” This stable footing is expected to aid in raising additional capital to fuel future developments and innovations.
About Relmada Therapeutics, Inc.
Relmada Therapeutics stands out in the clinical-stage biotechnology domain, focusing on transformative therapies that cater to both oncology and central nervous system-related conditions. As the company evolves, it remains focused on addressing unmet medical needs, driving forward with its promising candidates.
For further details about its therapies and ongoing research initiatives, check out the company’s official website at www.relmada.com.
Investor Relations and Media Contact
Investors and media representatives can reach out to Relmada for more information or inquiries. Brian Ritchie from LifeSci Advisors serves as the investor contact and is available via email at britchie@lifesciadvisors.com. Additionally, media inquiries can be directed to Corporate Communications at media@relmada.com.
Frequently Asked Questions
What is Relmada Therapeutics known for?
Relmada Therapeutics is a biotechnology company focused on creating innovative therapies for oncology-related and central nervous system conditions.
What recent achievement did Relmada Therapeutics accomplish?
The company recently regained compliance with Nasdaq's minimum bid price requirement, allowing its stock to remain listed on the market.
What are the main candidates in Relmada's pipeline?
Relmada’s lead candidates include NDV-01 and sepranolone, both of which are advancing through clinical development.
How can investors learn more about Relmada's offerings?
Investors can access detailed information about Relmada and their research initiatives through their official website.
Who should I contact for investor inquiries?
Brian Ritchie from LifeSci Advisors is the contact for investor relations, available at britchie@lifesciadvisors.com.
